Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02730455 : Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
PhasePhase 2
AgesMin: 18 Years Max: 80 Years
Eligibility
Key Inclusion Criteria:

- Clinical diagnosis of supratentorial acute ischemic stroke defined by LKN ?9 hours
prior to study treatment initiation

- Score of 5 to 23 points, inclusive, on the NIHSS at Screening

- Prior to index stroke, patient was able to perform basic activities of daily living
without assistance

- For those subjects who underwent a cranial MRI, there is at least 1 acute infarct
with a diameter of ?2 cm on baseline brain diffusion-weighted imaging

Key Exclusion Criteria:

- Rapidly improving or minor stroke symptoms

- Lacunar or isolated brainstem stroke based on clinical assessment and available acute
imaging studies

- Presence of acute intracranial hemorrhage on acute brain CT or MRI

- Severe stroke

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02730455      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740